{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:59:40Z","timestamp":1786982380918,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK","award":["221613"],"award-info":[{"award-number":["221613"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12325-024-03083-6","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T06:39:44Z","timestamp":1734935984000},"page":"1061-1074","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Medicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS\/LABA Before and After Initiation with Fluticasone Furoate\/Umeclidinium\/Vilanterol (FF\/UMEC\/VI)"],"prefix":"10.1007","volume":"42","author":[{"given":"Alan P.","family":"Baptist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Klimek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lalibert\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Schell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Forero-Schwanhaeuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Noorduyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosirene","family":"Paczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"3083_CR1","unstructured":"Centers for Disease Control and Prevention. Most recent national asthma data. 2021. https:\/\/www.cdc.gov\/asthma\/most_recent_national_asthma_data.htm. Accessed 18 Sept 2024."},{"key":"3083_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.anai.2010.10.017","volume":"106","author":"N Talreja","year":"2011","unstructured":"Talreja N, Baptist AP. Effect of age on asthma control: results from the National Asthma Survey. Ann Allergy Asthma Immunol. 2011;106:24\u20139.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3083_CR3","unstructured":"Centers for Medicare & Medicaid Services Office of Minority Health. Asthma disparities in Medicare fee-for-service beneficiaries. September 2020. https:\/\/www.cms.gov\/files\/document\/datasnapshot-asthma-sept2020.pdf. Accessed 3 Sept 2024."},{"key":"3083_CR4","unstructured":"Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention report 2024. May\u00a022, 2024. https:\/\/ginasthma.org\/wp-content\/uploads\/2024\/05\/GINA-2024-Strategy-Report-24_05_22_WMS.pdf. Accessed 30 Aug 2024."},{"key":"3083_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41533-023-00336-9","volume":"33","author":"S Zhang","year":"2023","unstructured":"Zhang S, White J, Hunter AG, et al. Suboptimally controlled asthma in patients treated with inhaled ICS\/LABA: prevalence, risk factors, and outcomes. NPJ Prim Care Respir Med. 2023;33:19.","journal-title":"NPJ Prim Care Respir Med"},{"key":"3083_CR6","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1080\/02770903.2018.1455858","volume":"56","author":"J Davis","year":"2019","unstructured":"Davis J, Trudo F, Siddall J, Small M. Burden of asthma among patients adherent to ICS\/LABA: a real-world study. J Asthma. 2019;56:332\u201340.","journal-title":"J Asthma"},{"key":"3083_CR7","unstructured":"National Heart Lung and Blood Institute. 2020 Focused Updates to the Asthma Management Guidelines. December 2020. https:\/\/www.nhlbi.nih.gov\/resources\/2020-focused-updates-asthma-management-guidelines Accessed 18 Sept 2024."},{"key":"3083_CR8","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/S0140-6736(19)32215-9","volume":"394","author":"JC Virchow","year":"2019","unstructured":"Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase\u00a03 trials. Lancet. 2019;394:1737\u201349.","journal-title":"Lancet"},{"key":"3083_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2023-001702","volume":"11","author":"B Numbere","year":"2024","unstructured":"Numbere B, Liu Y, Zhang S, Czira A, Lu Y. Characteristics, treatment patterns and burden of illness in US patients with asthma newly initiating multiple-inhaler triple therapy. BMJ Open Respir Res. 2024;11:e001702.","journal-title":"BMJ Open Respir Res"},{"key":"3083_CR10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jaip.2021.09.033","volume":"10","author":"J Oppenheimer","year":"2022","unstructured":"Oppenheimer J, Bogart M, Bengtson LGS, et al. Treatment patterns and disease burden associated with multiple-inhaler triple-therapy use in asthma. J Allergy Clin Immunol Pract. 2022;10:485-94.e5.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3083_CR11","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/all.15076","volume":"77","author":"A Agusti","year":"2022","unstructured":"Agusti A, Fabbri L, Lahousse L, Singh D, Papi A. Single inhaler triple therapy (SITT) in asthma: systematic review and practice implications. Allergy. 2022;77:1105\u201313.","journal-title":"Allergy"},{"key":"3083_CR12","unstructured":"GSK. New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm. September 9, 2020. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/fda-approves-trelegy-ellipta-as-the-first-once-daily-single-inhaler-triple-therapy-for-the-treatment-of-both-asthma-and-copd-in-the-us\/. Accessed 30 Aug 2024."},{"key":"3083_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","volume":"9","author":"LA Lee","year":"2021","unstructured":"Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase\u00a03A trial. Lancet Respir Med. 2021;9:69\u201384.","journal-title":"Lancet Respir Med"},{"key":"3083_CR14","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.2147\/JAA.S424055","volume":"16","author":"M Bogart","year":"2023","unstructured":"Bogart M, Germain G, Lalibert\u00e9 F, et al. Real-world study of single-inhaler triple therapy with fluticasone furoate\/umeclidinium\/vilanterol on asthma control in the US. J Asthma Allergy. 2023;16:1309\u201322.","journal-title":"J Asthma Allergy"},{"key":"3083_CR15","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1001\/jama.2021.7872","volume":"325","author":"LHY Kim","year":"2021","unstructured":"Kim LHY, Saleh C, Whalen-Browne A, O\u2019Byrne PM, Chu DK. Triple vs dual inhaler therapy and asthma outcomes in moderate to severe asthma: a systematic review and meta-analysis. JAMA. 2021;325:2466\u201379.","journal-title":"JAMA"},{"key":"3083_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e31186","volume":"10","author":"A Yamasaki","year":"2024","unstructured":"Yamasaki A, Tomita K, Inui G, Okazaki R, Harada T. Differences in the effectiveness of single, dual, and triple inhaled corticosteroid therapy for reducing future risk of severe asthma exacerbation: a systematic review and network meta-analysis. Heliyon. 2024;10:e31186.","journal-title":"Heliyon"},{"key":"3083_CR17","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1080\/14656566.2024.2366991","volume":"25","author":"R Laitano","year":"2024","unstructured":"Laitano R, Calzetta L, Matino M, Pistocchini E, Rogliani P. Asthma management with triple ICS\/LABA\/LAMA combination to reduce the risk of exacerbation: an umbrella review compliant with the PRIOR statement. Expert Opin Pharmacother. 2024;25:1071\u201381.","journal-title":"Expert Opin Pharmacother"},{"key":"3083_CR18","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3109\/02770903.2014.906607","volume":"51","author":"PW Sullivan","year":"2014","unstructured":"Sullivan PW, Slejko JF, Ghushchyan VH, et al. The relationship between asthma, asthma control and economic outcomes in the United States. J Asthma. 2014;51:769\u201378.","journal-title":"J Asthma"},{"key":"3083_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/02770903.2016.1194430","volume":"54","author":"PW Sullivan","year":"2017","unstructured":"Sullivan PW, Ghushchyan VH, Campbell JD, Globe G, Bender B, Magid DJ. Measuring the cost of poor asthma control and exacerbations. J Asthma. 2017;54:24\u201331.","journal-title":"J Asthma"},{"key":"3083_CR20","unstructured":"SSR Health. 2024. https:\/\/www.ssrhealth.com\/. Accessed Nov 2024."},{"key":"3083_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13601-019-0286-3","volume":"9","author":"A S\u00e1-Sousa","year":"2019","unstructured":"S\u00e1-Sousa A, Almeida R, Vicente R, et al. High oral corticosteroid exposure and overuse of short-acting beta-2-agonists were associated with insufficient prescribing of controller medication: a nationwide electronic prescribing and dispensing database analysis. Clin Transl Allergy. 2019;9:1\u201310.","journal-title":"Clin Transl Allergy"},{"key":"3083_CR22","unstructured":"Tarazi W, Welch P, Nguyen N, et al. Medicare beneficiary enrollment trends and demographic characteristics. Office of the Assistant Secretary for Planning and Evaluation (ASPE). March 2, 2022. https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/b9ac26a13b4fdf30c16c24e79df0c99c\/medicare-beneficiary-enrollment-ib.pdf. Accessed 30 Aug 2024."},{"key":"3083_CR23","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/j.mayocp.2017.08.005","volume":"92","author":"BP Yawn","year":"2017","unstructured":"Yawn BP, Han MK. Practical considerations for the diagnosis and management of asthma in older adults. Mayo Clin Proc. 2017;92:1697\u2013705.","journal-title":"Mayo Clin Proc"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03083-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03083-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03083-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T05:53:27Z","timestamp":1738389207000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03083-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3083"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03083-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"assertion":[{"value":"16 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alan P. Baptist reports grant support from GSK, AstraZeneca, and Teva. Guillaume Germain, Jacob Klimek, Fran\u00e7ois Lalibert\u00e9, and Robert C. Schell are employees of Analysis Group, a consulting company that has received research funds from GSK to conduct this study. Sergio Forero-Schwanhaeuser, Alison Moore, Stephen G. Noorduyn, and Rosirene Paczkowski are employees of GSK and hold financial equities in GSK. Stephen G. Noorduyn is also a PhD candidate at McMaster University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was considered exempt research under 45 CFR \u00a7 46.104(d)(4) as it involved only the secondary use of data that were de-identified in compliance with the Health Insurance Portability and Accountability Act (HIPAA): specifically, 45 CFR \u00a7 164.514.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}